Description

Product Description

AGPV (CAS 154485-78-6) is a synthetic tetrapeptide composed of four amino acid residues arranged in a bioactive sequence that enables modulation of host–parasite interactions. This compound has attracted attention in parasitology research for its potential role in the prevention of schistosome parasite infection, a major parasitic disease affecting millions of people worldwide.

Schistosomiasis, caused by blood flukes of the genus Schistosoma, remains a significant public health concern in tropical and subtropical regions. Peptide-based agents such as AGPV offer a novel strategy for interrupting parasite life cycles and infection establishment, especially in the early stages of host invasion.

 may act by interfering with surface protein recognition, blocking parasite adhesion to host cells, or modulating immune responses that facilitate parasite survival. Its small size and stability make it suitable for structural and biochemical studies exploring anti-parasitic mechanisms at the molecular level.

Preliminary studies suggest that tetrapeptides like AGPV can modulate protease activity, oxidative stress responses, and immune signaling cascades, thereby reducing the success of parasite colonization. Such mechanisms can be leveraged in designing vaccines or therapeutic leads against parasitic diseases.

Overall,  serves as a promising research compound for schistosome infection prevention, representing a bridge between peptide chemistry, immunology, and parasitology.

Product Specifications

Mechanism of Action

AGPV exerts its anti-parasitic and immunomodulatory effects by interacting with key molecular and cellular pathways involved in schistosome infection. As a small peptide, AGPV’s activity is based on specific amino acid motifs capable of interfering with parasite attachment and signaling.

1. Interference with Host–Parasite Binding

The early stages of schistosome infection involve complex molecular recognition events between parasite surface proteins and host cell receptors. may act as a competitive inhibitor, blocking these recognition sites and preventing successful parasite attachment and penetration.

2. Inhibition of Proteolytic Enzymes

Schistosomes secrete proteases to degrade host tissue barriers during invasion. AGPV has the potential to inhibit parasite protease activity, reducing tissue penetration and infection efficiency.

3. Immune System Modulation

AGPV may influence host immune signaling by modulating cytokine profiles or enhancing macrophage and T-cell responses. By reprogramming the immune system to recognize and attack invading parasites, AGPV helps to establish protective immunity in experimental models.

4. Reduction of Oxidative Stress

Parasitic infections often induce oxidative stress in host tissues. AGPV appears to enhance antioxidant defense mechanisms, protecting host cells from damage while simultaneously impairing parasite viability.

5. Potential Vaccine Adjuvant Role

Due to its immunomodulatory activity and low toxicity, AGPV could serve as a vaccine adjuvant or peptide component in schistosomiasis vaccine development. It may help induce memory immune responses that provide lasting protection against reinfection.

Collectively,  represents a multi-target peptide tool for studying host–parasite dynamics and identifying novel therapeutic strategies against schistosomiasis and related parasitic diseases.

Side Effects

Although AGPV is a research-use compound, and detailed toxicological studies are limited, general data from peptide-based analogs suggest the following possible effects:

• Low cytotoxicity at experimental concentrations.

• Potential immunogenic response upon repeated exposure in animal models.

• Mild local irritation possible in high-dose in vivo tests.

• Stable and biocompatible under physiological conditions, minimizing systemic toxicity.

Researchers are advised to adhere to proper laboratory safety practices and handle under standard peptide handling protocols.

Disclaimer

This product is for research use only (RUO). Not intended for human or veterinary use. Laboratory-grade compound supplied for controlled research applications.

Keywords

 CAS 154485-78-6, tetrapeptide, schistosome infection prevention, antiparasitic peptide, host–parasite interaction, protease inhibitor peptide, immunomodulatory peptide, oxidative stress modulation, parasitology research compound, peptide for tropical disease research, peptide drug discovery.

Shipping Guarantee

All peptide compounds are shipped under validated temperature-controlled conditions with full traceability and insurance coverage to ensure product integrity and quality.

Transaction Guarantee

We guarantee secure international transactions, authenticity verification, and availability of batch-specific analytical data (HPLC, MS) for all peptide compounds.